selpercatinib (Retsevmo)

following a full submission:

selpercatinib (Retsevmo®) is accepted for restricted use within NHSScotland.

Indication under review: as monotherapy for the treatment of adults and adolescents 12 years and older with advanced rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC).

SMC restriction: patients who require systemic therapy and have not previously received systemic therapy.
In a phase III study in patients with RET-mutant MTC, selpercatinib showed a statistically significant improvement in progression-free survival compared with the investigator’s choice of treatment.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

SMC has previously issued advice (SMC2370) for selpercatinib for the treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC) who require systemic therapy following prior treatment with cabozantinib and/or vandetanib. This advice remains valid.